Prophylaxis

Dr. Cindy Leissinger
MD

Dr. Leissinger is currently Professor of Medicine, and Clinical Professor of Pediatrics and Pathology at Tulane University, and is Chief of the Hematology/Oncology Division.  She is also Director of the Louisiana Center for Bleeding and Clotting Disorders.  She is a fellow of the American College of Physicians and a member of the American Society of Hematology and the International Society on Thrombosis and Haemostasis.  She currently serves as the president-elect of the Hemostasis and Thrombosis Research Society. 

Dr. Leissinger received her medical degree from Tulane University School of Medicine in New Orleans, Louisiana. She completed a residency in internal medicine at Tulane, a research fellowship in hematology at The National Institutes of Health in Bethesda, Maryland, and a clinical fellowship in hematology and medical oncology at Tulane.

In addition to caring for patients with coagulation disorders, Dr. Leissinger oversees an active research program that receives funding from the National Institutes of Health as well as numerous other federal and industry sources.  She participates in several clinical research groups, and has been an active investigator for many research studies related to bleeding disorders, with a particular interest in Factor VIII inhibitor development and management.

Key Publications

1. Leissinger C, Josephson C, Granger S, Konkle B, Kruse-Jarres R, Ragni M, Journeycake J, Neufeld E, Marder V,  Assmann S, for the RICH Study Investigators.  Rituximab for the treatment of inhibitors in hemophilia A: A phase II study.  Thromb Haemost. 2014 Jun; 12;112(3).

2. Leissinger C, Carcao M, Gill J, Journeycake J, Singleton T, Valentino L. Desmopressin (DDAVP) in the management of patients with bleeding disorders. Haemophilia. 2014 Mar;20(2):158-67.

3. Gringeri A, Leissinger C, Cortesi P, Jo H, Fusco F, Riva S, Mantovani L, and the ProFEIBA Study Group.  Health related quality of life in patients with haemophilia and inhibitors on prophylaxis with an anti-inhibitor complex concentrate (AICC): Results from the ProFEIBA Study.  Haemophilia. 2013 Sep;19(5):736-43.

4. Leissinger C, Gringeri A, Antmen B, Berntorp B, Biasoli B, Carpenter C, Cortesi P, Jo H, Kavakli K, Lassila R, Morfini M, Négrier C, Rocino A, Schramm W, Serban M, Uscatescu M, Windyga J, Zülfikar B,  Mantovani L.  Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med. 2011 Nov;365:1684-92. 

5. Leissinger C, Cooper D and Wilke C. Assessing the impact of age, race, ethnicity and inhibitor status on functional limitations of patients with severe and moderately severe hemophilia A.  Haemophilia. 2011 Nov; 17(6):884-889. 

Current Positions/Chairs:

  • Professor of Medicine
    Clinical Professor of Pediatrics and Pathology, Tulane University
  • Chief
    Section of Hematology/Oncology, Tulane University
  • Director
    Louisiana Center for Bleeding and Clotting Disorders

Key Institutions

  • Tulane University School of Medicine
    Hematology/Oncology
    New Orleans, USA

Research Activities

  • Dr. Leissinger participates in several clinical research groups, and has been an active investigator for many research studies related to bleeding disorders, with a particular interest in Factor VIII inhibitor development and management.

Research Interests

  • Factor VIII inhibitors
  • Treatment of patients with inhibitors
  • Thromboelastography in patients with thrombophilic states

Publications

April 24, 2017

An International Prophylaxis Study Group (IPSG) survey of prophylaxis in inhibitor positive children/adults with severe haemophilia

Authors
Carcao MD, Avila L, Leissinger C, Blanchette VS, Aledort L; Factor Utilization Expert Working Group on behalf of the International Prophylaxis Study Group (IPSG) and participating Survey Investigators.
Citation
Haemophilia 2017; 23 (5) : e444 - e447
April 21, 2017

An International Prophylaxis Study Group (IPSG) survey of prophylaxis in adults with severe haemophilia

Authors
Carcao M, Avila L, Leissinger C, Blanchette VS, and Aledort LM on behalf of the Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and participating Survey Investigators
Citation
Haemophilia 2017; 23 (5): e447 - e450
December 3, 2015

Hemophilia prophylaxis no longer just for children without inhibitors – increasing use of prophylaxis in other groups (children with inhibitors and adults with and without inhibitors)

Authors
Carcao M, Avila L, Blanchette V, Santagostino E, Escuriola-Ettingshausen C, Leissinger C, Lambert T, Aledort L on behalf of the International Prophylaxis Study Group (IPSG) and Survey Investigators.
Citation
Blood 2015; 126: 3535
June 20, 2015

Prophylaxis practices in children and adults with inhibitors

The XXV Congress of the International Society on Thrombosis and Haemostasis (June 20 - 25, 2015 – Toronto, Canada)
Authors
Carcao M, Avila M, Aledort L, Leissinger C on behalf of Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and other Survey Investigators
Citation